Compare Grab Holdings Ltd. (GRAB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Novo Nordisk A/S — how do they compare? Grab Holdings Ltd. trades at $3.19 (market cap $12.72B), while Novo Nordisk A/S trades at $38.44 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 13× Grab Holdings Ltd.'s market cap, and Novo Nordisk A/S pays a 4.71% dividend while Grab Holdings Ltd. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and Novo Nordisk A/S for 116 Days on average.
| GRAB | NVO | |
|---|---|---|
Market Cap | $12.72B | $165.31B |
Volume | 65,352,859 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $6.17 | $63.98 |
52-Week Low | $2.80 | $35.29 |
Typical Hold Time | 94 Days | 116 Days |
Enterprise Value | $8.46B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.08, up 0.33% with bearish technical signals but strong fundamentals. The company achieved profitability in 2025 with $268M net income and has beaten earnings estimates for three consecutive quarters. Recent developments include a $1.49B acquisition of Atome Financial and $30M in insider buying by the CEO, signaling confidence in growth prospects despite recent stock pressure.
GRAB presents a compelling turnaround story with accelerating revenue growth and margin expansion. The risk-reward appears favorable given the 92% analyst buy rating, though investors should monitor integration risks from the Atome acquisition and competitive pressures in Southeast Asian markets that could impact future profitability.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
